Malaria’s Innovation Moment

Session
Partners

Session Summary

Important
Quotations

“Malaria is a problem that besets many families and children around the world, but it is one we can solve, and one we can solve together.”
Dr. William Steiger
“Health is not a cost item, but an investment opportunity to drive greater prosperity, and they should champion that.”
Dr. Lutz Hegemann
“I hope and I believe that there is a lot of appetite and will to make this innovation reach the communities it needs.”
Dr. Jessica Vernon

Key
Takeaways

  • Malaria still kills about 600,000 people a year, mostly children under five. Hegemann stressed it is not a distant problem: changing climate, forced migration, and recent malaria deaths at Frankfurt airport show it is spreading. It also holds back economic growth and schooling. 
  • The malaria parasite is becoming resistant to current first-line drugs, with resistance documented in at least four or five African countries. Novartis’s next-generation drug, ganaplacide-lumefantrine, is in regulatory review and both treats patients and blocks transmission. 
  • After 25 years without a new malaria treatment, the world has lost its know-how for rolling one out quickly. The usual sequence of trials, then approval, then WHO guidance, then supply chains is too slow, so these steps need to run in parallel. New drugs should also be deployed carefully so they aren’t overused. 
  • About half of patients go to private pharmacies first because they are closer, faster, and better stocked, and care usually costs about a dollar. Maisha Meds works with roughly 6,000 pharmacies, clinics, and drug shops in four countries. It uses clinical checklists, testing before treatment, co-payments, and reimbursement to raise the quality of care, which also lays groundwork for future health insurance. 
  • Private-sector data reveals trends other sources miss. Maisha Meds sees 35 million patient encounters a year, about 12% of them malaria. Only about 10% of drugs sold in the private sector are quality-assured, compared with 90% in the public sector, and use of injectable artesunate has risen tenfold in a decade. 
  • Malaria now looks very different from place to place: some countries are near elimination, some still carry a high burden, and conflict zones see outbreaks. In the DRC’s current Ebola outbreak, more people are estimated to be dying of malaria than of Ebola. With donor funding shrinking, a full toolbox of new drugs, spatial repellents, and improved bed nets, used in a data-driven and locally led way, can do more with less. 
  • Steiger noted there has been more malaria innovation in the last 18 months than in the previous 25 to 30 years. The panel was optimistic, but success depends on sustained funding, stronger health systems, and the shift from donor-funded programs toward local leadership and domestic financing. 

Action
Items

  • Regulators, WHO, manufacturers, and countries should prepare approval, guidelines, and supply chains for new antimalarials at the same time rather than one after another. 
  • Deploy new drugs in a targeted way, using resistance maps and medicine consumption data, so they reach the patients who benefit most and stay effective longer. 
  • Bring private pharmacies into national malaria strategies. This should include quality-assured drugs, testing before treatment, and reimbursement models that reward good care. 
  • Feed private-sector and community-level data into surveillance, policy, and funding decisions. 
  • National governments should increase domestic financing and leadership for malaria programs, treating health as an investment in prosperity rather than a cost. 
  • The next WHO Director-General should act with urgency on new product approvals, listen to grassroots voices and data, and work closely with the private sector.